Capricor Therapeutics, Inc. (NASDAQ:CAPR) stock soared on Wednesday after the company announced positive topline data from the Phase 3 HOPE-3 trial for its lead cell therapy candidate, deramiocel.
The data release and stock surge triggered a dramatic response from controversial former pharma executive and prominent short-seller Martin Shkreli, who had publicly bet against Capricor's success.
Benzinga reached out to Capricor Therapeutics for comment, but did not receive an immediate response.
The furious rally in CAPR stock represents a major reversal and a massive paper loss for any short position held going into the data readout — causing a “short squeeze” and driving the stock price even higher.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.